UCSF adult and pediatric clinical trials

UCSF Brain Tumor Center Clinical Trials

Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors. 

Identify Relevant Clinical Trials
Clinical Trial Phase
Intervention Model
Treatment Modality
Which of the following treatments has the patient already received?*
Genetic Features*
  • Recruiting Recruiting
  • Pediatrics Pediatrics
  • On Hold On Hold
Conditions
Glioma
Astrocytoma
Pilocytic astrocytoma (grade I)
Diffuse astrocytoma (grade II)
Pleomorphic xanthoastrocytoma (grades II-III)
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Brainstem Glioma
Diffuse Midline Glioma
This phase I clinical trial will evaluate the safety and dosage a novel drug called TAK-580, for treating children and young adults with recurrent gliomas or other solid tumors.
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
DCC-2618 is an orally administered drug designed to inhibit the activity of proteins called KIT and PDGFRα. KIT and PDGFRα are proteins that are mutated or abnormally active in variety of cancer cell types; when mutated, these proteins can increase tumor cell proliferation and resistance to chemotherapy.
Conditions
Glioma
Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Brainstem Glioma
Diffuse Midline Glioma
Atypical Teratoid / Rhaboid Tumor (AT/RT)
Subependymal giant cell astrocytoma (grade I)
Medulloblastoma
Choroid Plexus Tumors
The purpose of this Phase I clinical trial is to evaluate the safety and efficacy of the drug ramucirumab, in treating children with recurrent or refractory solid tumors, including CNS tumors.
Conditions
Glioma
Astrocytoma
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Brainstem Glioma
Diffuse Midline Glioma
Atypical Teratoid / Rhaboid Tumor (AT/RT)
Subependymal giant cell astrocytoma (grade I)
Choroid Plexus Tumors
Medulloblastoma
The purpose of this Phase I clinical trial is to study the side effects and best dose of entinostat in treating pediatric patients with recurrent or refractory solid tumors.
Conditions
Glioma
Oligodendroglioma
Astrocytoma
Diffuse astrocytoma (grade II)
The purpose of this study is to investigate the effect of a drug called everolimus (RAD001, or Afinitor) alone or in combination with temozolomide (a chemotherapy drug) in treating patients with newly diagnosed low-grade glioma. 

Stay Informed